Sumitomo Dainippon Pharma Co., Ltd. provided financial guidance for the year ending March 31, 2023. For the period, the company expected Net sales of JPY 550,000 million, Operating profit of JPY 24,000 million, Net profit attributable to owners of parent of JPY 22,000 million and EPS of JPY 55.37.